Home » PAIN THERAPEUTICS ENDS DEVELOPMENT OF BOWEL DRUG
PAIN THERAPEUTICS ENDS DEVELOPMENT OF BOWEL DRUG
Pain Therapeutics Inc. (PTIE.O: Quote, Profile, Research) said on Friday it will discontinue development of its experimental treatment for irritable bowel syndrome after a pivotal-stage trial failed to show that the drug is effective. The company said a Phase III trial of the drug, known as PTI-901, showed meaningful relief of symptoms in the second month of treatment, but the drug did not demonstrate a meaningful benefit in the third month of treatment, which was the trial's primary goal.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May